---
schema_version: "secwatch.filing_event.v1"
accession: "0001140361-22-020321"
form_type: "8-K"
ticker: "INVA"
cik: "0001080014"
company_name: "Innoviva, Inc."
filed_at: "2022-05-24T23:59:59+00:00"
generated_at: "2026-06-25T07:30:26.326321+00:00"
event_type: "m_and_a"
sentiment: "neutral"
materiality_score: 0.7
calibrated_materiality_score: 0.7
confidence: "high"
source: SEC EDGAR
---

# Innoviva to acquire Entasis Therapeutics for $2.20/share cash tender offer

## Summary
- Offer price of $2.20 per share; all-cash transaction valued at implied equity value of ~$80M (based on 36.4M shares outstanding).
- Merger agreement unanimously approved by boards of Innoviva, Merger Sub, and Entasis.
- Support agreements with TPG GP A, LLC and independent directors covering ~2.32% of shares; they will tender in the offer.
- Tender condition requires at least one more than 50% of shares not owned by Innoviva or Entasis CEO; no financing contingency disclosed.
- Entasis options and RSUs will be converted into cash or Innoviva stock; warrants replaced with Innoviva warrants.

## SEC filing metadata
- accession: 0001140361-22-020321
- form_type: 8-K
- ticker: INVA
- cik: 0001080014
- company_name: Innoviva, Inc.
- filed_at: 2022-05-24T23:59:59+00:00
- event_type: m_and_a
- sentiment: neutral
- materiality_score: 0.7
- calibrated_materiality_score: 0.7
- confidence: high
- sec_items: 1.01, 8.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1080014/000114036122020321/0001140361-22-020321-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1080014/000114036122020321/ny20004305x1_8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001140361-22-020321
- JSON: https://secwatch.observer/filing/0001140361-22-020321.json
- Plain text: https://secwatch.observer/filing/0001140361-22-020321.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.